



## **Syndax to Participate in Two Upcoming Conferences**

WALTHAM, Mass., March 12, 2015 -- Syndax Pharmaceuticals, Inc., today announced that Arlene Morris, president and chief executive officer, will be participating in two upcoming conferences.

- **22nd Annual Future Leaders in the Biotech Industry Conference:** Arlene Morris will be presenting a corporate overview on Friday, March 20, 2015 at 3:30 p.m. EDT at the Millennium Broadway Hotel & Conference Center in New York City.
- **BIO Asia International Conference:** Arlene Morris will be participating in a panel titled “Emerging Deal-Making Trends in Japan” on Wednesday, March 25, 2015 at 9:00 a.m. JST at the Grand Hyatt Tokyo.

### **About Syndax**

Syndax is developing entinostat, an oral, highly selective HDAC inhibitor with epigenetic and immunomodulatory activity that is being evaluated in multiple combination regimens for the treatment of patients with therapy-resistant cancers. Entinostat has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in HR+ advanced (locally advanced or metastatic) breast cancer. A pivotal Phase 3 clinical study, being conducted under a special protocol assessment (SPA), combining entinostat with exemestane for the treatment of hormone receptor-positive metastatic breast cancer is currently enrolling. Syndax is also developing an immuno-oncology platform to improve responsiveness to checkpoint inhibitors based on entinostat’s ability to down-regulate immune suppressor cells. Syndax holds rights to entinostat in most major markets.